Clinical Trials on Locally Advanced Melanoma in United States

Total 4750 results

University of Miami

Completed

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

Melanoma (Skin)

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Melanoma (Skin)

United States
St. Luke's Medical Center

Unknown

Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Baylor Health Care System
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage III Skin Melanoma

United States
Fred Hutchinson Cancer Center
National Institute of Nursing Research (NINR); Peacefully, Inc.

Recruiting

Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer

Hematopoietic and Lymphoid System Neoplasm | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Case Comprehensive Cancer Center

Completed

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

Metastatic or Unresectable Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy

Stage IV Skin Melanoma

United States
Inova Health Care Services
Genentech, Inc.

Withdrawn

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Stage IIIB-C Melanoma

United States
Baylor Research Institute

Completed

Combined Modality Treatment for Patients With Stage IV Melanoma

Malignant Melanoma Stage IV

United States
Georgetown University
ERYtech Pharma

Active, not recruiting

Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
California Pacific Medical Center Research Institute
M.D. Anderson Cancer Center

Recruiting

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Metastatic Melanoma

United States
Case Comprehensive Cancer Center

Active, not recruiting

Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting

Stage III Melanoma | Stage IV Cutaneous Melanoma

United States
Oxford University Hospitals NHS Trust
University of Oxford; Barts & The London NHS Trust; Ninewells Hospital

Completed

Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors (EUNASS)

Melanoma Stage III | Melanoma, Stage II | Melanoma, Stage I

United Kingdom
Immunocore Ltd
AstraZeneca

Completed

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Malignant Melanoma

United States
University of Michigan Rogel Cancer Center

Active, not recruiting

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Metastatic Melanoma | Liver Metastases | Melanoma, Mucosal | Melanoma, Ocular | Melanoma, Cutaneous

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Liver Metastases | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Extraocular Extension Melanoma

United States
National Cancer Institute (NCI)

Recruiting

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Locally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Metastatic Sinonasal Adenocarcinoma | Locally Advanced Sinonasal Adenocarcinoma | Metastatic Large-cell Neuroendocrine Carcinoma | Locally Advanced Large-cell Neuroendocrine Carcinoma | Metastatic Olfactory Neuroblastoma | Locally Advanced... and other conditions

United States
Dartmouth-Hitchcock Medical Center

Terminated

Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer

Locally Advanced Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

Recurrent Melanoma | Stage III Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Melanoma | Cervical Cancer | HCC | Gastric Cancer | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Locally Advanced or Metastatic Solid Tumors | TNBC | Clear Cell RCC

Korea, Republic of, Netherlands, Spain, United States, Australia, Canada, Belgium
Vical

Completed

A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma

Metastatic Melanoma

United States
Northwestern University

Terminated

A Novel Treatment for Metastatic Melanoma

Metastatic Melanoma

United States
NewLink Genetics Corporation

Completed

Vaccine Treatment for Advanced Malignant Melanoma

Malignant Melanoma

United States
Acrotech Biopharma Inc.

Completed

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

Malignant Melanoma

United States
University of Maryland, Baltimore
National Cancer Institute (NCI)

Terminated

0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma

Melanoma (Skin)

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Pawel Kalinski
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Stanford University
National Cancer Institute (NCI)

Completed

Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma

Recurrent Melanoma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Duke University
National Cancer Institute (NCI)

Completed

Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

Melanoma (Skin)

United States
Aurora Health Care

Terminated

Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Beth Israel Deaconess Medical Center

Unknown

Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma

Melanoma (Skin)

United States

Clinical Trials on Locally Advanced Melanoma in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations